Reprogrammed Cells in Disease Modeling and Drug Discovery II

Dear Colleagues,

Traditional cancer models, including cell lines and animal models, have been widely used but have seen limited applications in both basic and clinical cancer research. Patient-derived model systems are needed for modeling human diseases and precision medicine. Genomics-based precision oncology only helps 2-20% of patients with solid cancer, and as such, functional diagnostics and patient-derived models are needed for precision cancer biology. Induced pluripotent stem cells (iPS), organoids, and conditional reprogramming (CR) are currently used widely for patient-derived cell models for disease and precision medicine. Both organoids and CR technologies have been cited in two NCI programs—PDMR (patient-derived cancer model repository) and HCMI (human cancer model initiatives), the latter of which will be distributed through ATCC. These cells can be easily manipulated in vitro, and thus, these patient-derived cells could be used for next-generation disease models. In this Special Issue, we will focus on the applications of cell reprogramming technologies (including iPS, CR, organoids, and others) in disease modeling including cancer, inflammatory, genetic diseases, infectious diseases (virus infection models), and drug discovery.

Prof. Dr. Xuefeng Liu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.